Avecho Biotechnology will proceed to full enrollment in its phase III insomnia trial after an independent board found no serious adverse events in an interim analysis of its TPM-enhanced CBD capsule. The company is now preparing to engage with the FDA and international regulators to determine potential commercial pathways for the treatment.
Eli Lilly and Company has completed its acquisition of Centessa Pharmaceuticals, securing a portfolio of clinical-stage orexin receptor 2 agonists. This strategic move aims to accelerate the development of new treatments for narcolepsy and other sleep-wake disorders.
Research presented at ATS 2026 reveals that positional therapy conditions patients to avoid back-sleeping, maintaining obstructive sleep apnea control for up to a year after device withdrawal.
What can sleep physicians do when obstructive sleep apnea patients can't afford every recommended therapy?
The acquisition of PONM gives Nexalin ownership of the AI-integrated software supporting its HALO Clarity program, preparing for a 160-participant trial for moderate-to-severe insomnia.
The acquisition adds the FDA-cleared, non-pharmacologic Nidra TOMAC therapy to Resmed’s portfolio, expanding its reach into the treatment of restless legs syndrome.
The new dual-product system aims to support the 24-hour wellness cycle, accompanied by a strategic partnership with the Calm app to offer curated sleep content.
A retrospective study explores how surgical and pharmacologic weight-loss strategies stack up in cost, effectiveness, and health outcomes.
A mastery-based cognitive-behavioral model centers on "nightmare efficacy" to help clinicians create personalized treatment plans for youth.